16
Jan
2012
SurgiQuest, Inc.: Series D $19M
Posted in I - Series D, Q - 3Q11, R - NORTH EAST, X - Device (Laparoscopic), XX - CT
SurgiQuest (Milford, CT) a commercial-stage medical device company focused on minimally invasive surgery products for access to the abdominal cavity, closed a $19M Series D financing. Participants include River Cities Capital Funds, Fletcher Spaght Ventures, California Technology Ventures and Aphelion Medical Fund.
Thanx for your patience as we catch-up.
20
May
2011
Rib-X Pharmaceuticals, Inc.: Series E $20M
Posted in I - Series E, Q - 1Q11, R - NORTH EAST, X - Antiinfective, X - Bronchitis, X - MRSA, X - Pneumonia, XX - CT
Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $20M Series E financing. Participants have included Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.
29
Nov
2010
Helix Therapeutics, Inc.: Series A $2.5M
Posted in I - Series A, Q - 4Q10, R - NORTH EAST, X - Hematology, X - Immunology, X - Lysosomal Storage, XX - CT
Helix Therapeutics (New Haven, CT) a preclinical-stage company developing triplex-forming oligonucleotides to target genome modification with a focused on hemoglobin, immune and lysosomal storage disorders, closed a $2.5M Series A financing. Participants include Canaan Partners and Connecticut Innovations.
25
Oct
2010
Cara Therapeutics, Inc.: Series D $15M
Posted in I - Series D, Q - 3Q10, R - NORTH EAST, X - Inflammation, X - Pain, XX - CT
Cara Therapeutics (Shelton, CT) a clinical-stage small molecule company focused on pain and inflammation, closed a $15M Series D financing. Participants include Rho Ventures, Alta Partners, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Mitsubishi International and MVM Life Science Partners.
04
Mar
2010
12
Oct
2009
Kolltan Pharmaceuticals, Inc.: Series A $5M
Posted in I - Series A, Q - 3Q09, R - NORTH EAST, X - Oncology, XX - CT
Kolltan Pharmaceuticals (New Haven, CT) an early-stage developer of oncology therapeutics leveraging the receptor tyrosine kinase targets closed a $5M Series A, bring the total financing round to $40M. Participants include Purdue Pharma, HBM Bioventures, the Pritzker family and Diaz and Altschul Capital Management.
03
May
2009
Marinus Pharmaceuticals, Inc.: Series B $20M
Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - CNS, X - Depression, X - PTSD, X - Seizures, XX - CT
Marinus Pharmaceuticals (Branford, CT) a clinical-stage company focused on reformulation and development of therapeutics for the treatment of CNS, psychiatric and pain disorders, closed a $20M Series B financing. Participants include Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners.
11
Feb
2009
Rib-X Pharmaceuticals, Inc.: Series D $25M
Posted in I - Series D, Q - 1Q09, R - NORTH EAST, X - Antiinfective, X - Bronchitis, X - Pneumonia, XX - CT
Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $25M Series D financing. Participants include Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.
12
Jan
2009
OnBioVC PARTNERS
-
